Originally published by our sister publication Specialty Pharmacy Continuum
By Myles Starr
The FDA has approved more than 40 cellular and gene therapy (CGT) products to date. However, there is a lack of regulation to mitigate the risks these new treatments pose to healthcare workers, according to a paper in the American Journal of Health-System Pharmacy. The authors proposed standard operating procedures (SOPs) for handling emerging therapies to protect pharmacists who come into contact with